Activation of Receptor for Advanced Glycation End Products
Open Access
- 19 March 1999
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 84 (5) , 489-497
- https://doi.org/10.1161/01.res.84.5.489
Abstract
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. One class of RAGE ligands includes glycoxidation products, termed advanced glycation end products, which occur in diabetes, at sites of oxidant stress in tissues, and in renal failure and amyloidoses. RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature. Interaction of RAGE with these ligands enhances receptor expression and initiates a positive feedback loop whereby receptor occupancy triggers increased RAGE expression, thereby perpetuating another wave of cellular activation. Sustained expression of RAGE by critical target cells, including endothelium, smooth muscle cells, mononuclear phagocytes, and neurons, in proximity to these ligands, sets the stage for chronic cellular activation and tissue damage. In a model of accelerated atherosclerosis associated with diabetes in genetically manipulated mice, blockade of cell surface RAGE by infusion of a soluble, truncated form of the receptor completely suppressed enhanced formation of vascular lesions. Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands. Future studies using mice in which RAGE expression has been genetically manipulated and with selective low molecular weight RAGE inhibitors will be required to definitively assign a critical role for RAGE activation in diabetic vasculopathy. However, sustained receptor expression in a microenvironment with a plethora of ligand makes possible prolonged receptor stimulation, suggesting that interaction of cellular RAGE with its ligands could be a factor contributing to a range of important chronic disorders.Keywords
This publication has 66 references indexed in Scilit:
- Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brainNeuroscience Letters, 1996
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996
- N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue ProteinsBiochemistry, 1995
- Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.Journal of Clinical Investigation, 1995
- Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a).Journal of Clinical Investigation, 1993
- Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.Journal of Clinical Investigation, 1993
- Role of Oxidative Stress in Development of Complications in DiabetesDiabetes, 1991
- Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988
- Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitusThe American Journal of Cardiology, 1987
- Sorbitol, Phosphoinositides, and Sodium-Potassium-ATPase in the Pathogenesis of Diabetic ComplicationsNew England Journal of Medicine, 1987